Atlanta Behavioral Research LLC

1. Janssen Research & Development, LLC $729,316 108 payments
2. Allergan Inc. $280,125 67 payments
3. Otsuka Pharmaceutical Development & Commercialization, Inc. $259,086 10 payments
4. AbbVie, Inc. $103,239 42 payments
5. Neurocrine Biosciences, Inc. $72,518 21 payments
6. ITI, Inc. $30,838 8 payments
7. Sumitomo Pharma America, Inc. $18,532 47 payments
8. Supernus Pharmaceuticals, Inc. $13,000 2 payments
9. Boehringer Ingelheim Pharmaceuticals, Inc. $10,750 1 payment
10. Pfizer Inc. $9,020 5 payments

1. A Double blind Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Subjects Who Are Assessed to be at Imminent $262,327 31 payments
2. A Double blind Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Subjects Who Are Assessed to be at Imminent Risk for Suicide $178,357 36 payments
3. A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide $126,847 10 payments
4. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $94,329 18 payments
5. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $88,498 2 payments
6. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $72,696 3 payments
7. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Nbi-98854 in Pediatric Subjects With Tourette Syndrome $72,518 21 payments
8. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $66,249 17 payments
9. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder $48,499 1 payment
10. A 6-week, Multicenter, Randomized, Double-blind, Parallel-group,Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Participants (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorde $41,760 8 payments

1. Patient care $13,000 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.